Media Centre

Featured Media Release

14 Nov 2013 - GSK award shines light on seismic change to epilepsy diagnosis

GSK has awarded Professor Ingrid Scheffer the 2013 GlaxoSmithKline Award for Research Excellence (ARE) for helping to transform the diagnosis of epilepsy.


Media Releases

Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and COPD

GSK Australia and Theravance, Inc. (NASDAQ: THRX) have proudly announced today that the Therapeutic Goods Administration (TGA) has approved Breo Ellipta.



GSK innovation helps relieve smokers cravings in 50 seconds

GSK Australia launched today a new innovative product Nicabate Oral Strips that relieve the urge to smoke in just 50 seconds. Nicabate Oral Strips are the first and only nicotine oral strips in the country.



Illuminate your smile with the new Macleans® High Definition™ White range

Whether having a laugh with friends, showcasing ideas at a business meeting or embarking on a first date with that special someone – an illuminated smile can make you look and feel your best at all times. So light-up your day and ensure you're...



GSK brings New Zealand to the forefront in new Panadol® brand campaign

A Kiwi father and son will star in a brand new Panadol campaign to be aired on television screens globally, bringing New Zealand to the forefront of what is a new direction for the trusted brand.




GSK is in the process of voluntarily recalling from warehouses and distributors a number of batches of nicotine lozenges sold globally, after we detected manufacturing issues affecting some batches. In some cases, the lozenges were larger or...



New PBS listing for patients with advanced soft tissue sarcoma

Treatment options for advanced Soft Tissue Sarcoma (STS) have been broadened with a new Pharmaceutical Benefits Scheme (PBS) listing for Votrient® (pazopanib hydrochloride)1 providing a targeted treatment option for physicians and their patients.



TGA approves GSK’s combination of TAFINLAR®(dabrafenib) and MEKINIST® (trametinib)

GSK Australia announced today that the Therapeutics Goods Administration (TGA) has approved the combination of two oral targeted therapies, MEKINIST (trametinib) and TAFINLAR (dabrafenib), for the treatment of patients with BRAF V600 mutation...



Supply of Varilrix® and Priorix-Tetra® resumes

Supply of Varilrix® and Priorix-Tetra® will resume gradually by



Poppy Crop Security Update

GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security following recent media reports.



Supply of Varilrix® and Priorix-Tetra®

GSK recently identified a global manufacturing issue relating to some of our varicella-containing vaccines which has resulted in temporary disruptions to supply of Varilrix® and Priorix-Tetra®.


1 2 3 4 5 6 7 8 9 10 11 >